Skip to main content
Parker Cancer ends here

Innovations

Promise into
Progress

Discovery is just the beginning. Parker Innovations is the connective tissue of the entire Parker model. In the chasm between academia and industry, where science too often loses steam, Innovations propels discoveries forward — and turns promise into progress. 

Scientists looking at information on a screen in a lab setting

As stewards of all intellectual property generated across our network, our Innovations team maintains a bird’s-eye view of the most exciting emerging science. From that vantage point, we’re able to identify breakthroughs with the greatest potential and chart the best path forward. That can mean connecting the breakthrough with other, complementary IP, licensing it to a biotech or pharmaceutical partner, or spinning off a new company. Our objective is always the same: ensuring momentum is never lost, and that life-saving treatments reach the patients who need them.

Brain scan results on a light box. The scan has a black background with blue print of the scan

Made Possible by Parker

The gap between lab discovery and commercial development is a big one. It's often a dramatic drop-off where scientific breakthroughs can falter and even fail. Parker Institute's IP team helps bridge the gap, giving investigators the support they need to navigate the complex path to biotech and pharmaceutical commercialization — so more discoveries have a chance to make a difference in the lives of more patients, more quickly.

We have supported the licensing and optioning of over 150 inventions to biotech and pharma partners.

56

Licensed technologies 
and growing

Eli Lilly acquired Kelonia Thereputics — utilizing Parker IP for viral targeting of hematopoietic stem cells — for $3.2B

Read more
12

Parker inventions were licensed or optioned in 2025.

Portrait of a scientist in a lab

Stronger Together

Scientific research can be competitive, as can commercialization of promising discoveries. Not here. Parker Institute's ambitious agenda demands whole-hearted collaboration across academia and industry. To achieve our mission, we partner with pharmaceutical companies, biotechs, and nonprofits that share our belief that a world without cancer is possible — and that immunotherapy is the best way to get there.

Contact us to discuss our portfolio of licensable IP.